Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAminex Regulatory News (AEX)

Share Price Information for Aminex (AEX)

Share Price is delayed by 15 minutes
Get Live Data
2.625    -0.05 (-1.85%)
Bid:
2.60
Ask:
2.65
Spread: 0.05 (1.923%)
Market Cap: £118.59m
AEX Live PriceLast checked at - London Stock Exchange

Intraday Aminex Share Chart

Further re: Rights Issue

18 Jul 2007 15:51

Aminex PLC18 July 2007 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN PART OR IN WHOLE IN OR INTO THEUNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA OR JAPAN FOR IMMEDIATE RELEASE 18 JULY 2007 Aminex PLC ("Aminex" or "the Company") Further re: Rights Issue Placing of 2,705,476 New Ordinary Shares not taken up in the Rights Issue Further to the announcement issued on 16 July 2007 that Aminex had receivedvalid acceptances in respect of 14,465,371 New Ordinary Shares, representingapproximately 51.4 per cent. of the New Ordinary Shares offered to QualifyingShareholders under the 1 for 6 Rights Issue, the Company announces that Davy hasprocured subscribers for 2,705,476 New Ordinary Shares (including theentitlement of overseas shareholders and fractional entitlements) which were notvalidly taken up in the Rights Issue, at a price of Stg£0.21 per New OrdinaryShare. The remaining New Ordinary Shares available under the Rights Issue willnot be issued. Subscribers for Rights Issue Shares are entitled to 1 New Warrant for every 2Rights Issue Shares subscribed for so long as they are recorded as theregistered holder of those Rights Issue Shares at Admission on 2 August 2007(the date on which the Rights Issue Shares and associated New Warrants areexpected to be credited to CREST stock accounts). The Company has raised gross proceeds of US$29.27m from the Firm Placing and theRights Issue (including this Placing). Following completion of the Rights Issue, the Company has 242,031,747 OrdinaryShares in issue and 36,526,673 New Warrants in issue. There are no net proceeds from the sale of these New Ordinary Shares, afterdeduction of the Rights Issue Price of Stg£0.20 per share and relevant costs, tobe paid to those shareholders who have not taken up their Rights Issueentitlements. Definitions used in the Prospectus dated 23 May 2007 shall have the samemeanings when used in this announcement. For further information: Aminex PLCBrian Hall Tel: +44 (0) 20 7291 3100 DavyEugenee Mulhern / Fergal Meegan Tel: +353 (0) 1 679 6363 BridgewellAndrew Matharu Tel: + 44 (0) 20 7003 3105 Pelham Public RelationsArchie Berens Tel: +44 (0) 20 7743 6679 Davy Corporate Finance Limited and J&E Davy (collectively ''Davy'') (each ofwhich is regulated in Ireland by the Irish Financial Services RegulatoryAuthority) and Bridgewell Limited (''Bridgewell'') (which is regulated in the UKby the Financial Services Authority) are acting exclusively for Aminex inconnection with the requirements of the Irish Stock Exchange and the UK ListingAuthority and for no one else and will not be responsible to any other personfor providing the protection afforded to customers of Davy or Bridgewell nor forproviding advice in connection with this announcement. Participation in the Rights Issue is not and has not been available toshareholders resident in the United States, Australia, Canada, South Africa orJapan or any other jurisdiction where it would be unlawful to offerparticipation. This announcement does not constitute, or form part of, an offer of, or thesolicitation of any offer to subscribe for or buy, any of the Ordinary Shares orWarrants to be issued or sold in connection with the Placing and/or RightsIssue. Investors should not subscribe for or purchase any securities referred toin this announcement except on the basis of information in the Prospectuspublished by the Company on 23 May 2007 in connection with the Placing andRights Issue. The offer of the Ordinary Shares and Warrants in certain jurisdictions may berestricted by law and therefore potential investors should inform themselvesabout and observe any such restrictions. This announcement is not forpublication or distribution, directly or indirectly, in or into the UnitedStates. This announcement is for information only and does not constitute anoffer or invitation to acquire or dispose of Ordinary Shares or Warrants in theUnited States. The Placing and Rights Issue will not be an offer of securitiesfor sale in the United States. Securities may not be offered or sold in theUnited States absent registration or an exemption from registration. TheOrdinary Shares and Warrants have not been and will not be registered under theUS Securities Act of 1933, as amended ('the Securities Act'), or with anysecurities regulatory authority of any state or other jurisdiction of the UnitedStates, and may not be offered or sold in the United States, except pursuant toan exemption from, or in a transaction not subject to, the registrationrequirements of the Securities Act. There will be no public offering of OrdinaryShares or Warrants in Aminex in the United States. Past performance is no guide to future performance and persons needing adviceshould consult an independent financial adviser. The distribution of this announcement may be restricted by law. No action hasbeen taken that would permit the possession or distribution of this announcementin any jurisdiction where action for that purpose is required. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Jun 20269:49 amRNSTotal Voting Rights
11th May 20264:07 pmRNSDirector/PDMR Shareholding
11th May 20264:02 pmRNSExercise of Options and Total Voting Rights
30th Apr 20265:29 pmRNSDirector/PDMR Shareholding
28th Apr 20269:11 amRNSFinal Results and Annual Report 2025
12th Mar 20264:43 pmRNSHolding in Company
12th Mar 20264:40 pmRNSPerson Closely Associated Dealing
27th Feb 202612:11 pmRNSExercise of Options and Total Voting Rights
3rd Feb 20261:45 pmRNSNtorya Operations Update
23rd Jan 20267:00 amRNSNtorya to Madimba Pipeline
18th Dec 20257:00 amRNSNtorya Operations Update
31st Oct 20257:00 amRNSTotal Voting Rights
6th Oct 20257:00 amRNSStrategic Placing to fund Aminex to Ntorya Revenue
26th Sep 20257:00 amRNS2025 Half-Yearly Financial Report
27th Aug 20257:00 amRNSNtorya Operations Update
24th Jul 20254:03 pmRNSResult of AGM
17th Jul 202512:00 pmRNSNtorya Operations Update
3rd Jul 20253:15 pmRNSNtorya to Madimba Pipeline Contract Awarded
30th Jun 202511:31 amRNSNotice of AGM
30th Apr 20254:21 pmRNS2024 Annual Report and Accounts
29th Apr 20254:53 pmRNSFinal Results and Annual Report 2024
5th Mar 20257:00 amRNSNtorya Operations Update
30th Sep 20247:00 amRNS2024 Half-Yearly Financial Report
11th Sep 20242:27 pmRNSNtorya Development Licence handover ceremony
27th Jun 202412:55 pmRNSResult of AGM
19th Jun 20243:02 pmRNSDirector/PDMR Dealing
19th Jun 20242:31 pmRNSExercise of Options and Total Voting Rights
3rd Jun 20247:00 amRNSNotice of AGM
23rd May 20244:04 pmRNSNtorya Development Licence Granted
10th May 20247:00 amRNSUpdate on Ntorya to Madimba Pipeline
29th Apr 20247:01 amRNSFinal Results and Annual Report 2023
29th Apr 20247:00 amRNSFunding Facility agreed with Eclipse Investments
29th Feb 20247:00 amRNSRuvuma Seismic Update
10th Jan 20242:49 pmRNSRuvuma Gas Sales Agreement signed
31st Oct 20235:00 pmRNSKiliwani Operations Update
29th Sep 20237:00 amRNS2023 Half-Yearly Financial Report
1st Sep 20237:00 amRNSDirectorate Change
13th Jul 20234:26 pmRNSResult of AGM
12th Jul 20237:00 amRNSRuvuma Operations Update
20th Jun 20237:00 amRNSNotice of AGM
2nd Jun 20233:13 pmRNSDirector/PDMR Shareholding
26th May 20237:00 amRNSPublication of New Research
28th Apr 20236:13 pmRNSFinal Results and Annual Report 2022
2nd Mar 20237:00 amRNSStrategy/Company/Ops Update
6th Feb 202311:05 amRNSSecond Price Monitoring Extn
6th Feb 202311:00 amRNSPrice Monitoring Extension
6th Feb 20239:05 amRNSSecond Price Monitoring Extn
6th Feb 20239:00 amRNSPrice Monitoring Extension
28th Nov 202211:05 amRNSSecond Price Monitoring Extn
28th Nov 202211:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.